文献速递消化道肿瘤放疗放疗物理与技术

在线MR引导剂量递增放疗用于远端直肠癌器官保留

Online MR guided dose escalated radiotherapy for organ preservation in distal rectal cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2022-10-15

本研究在5例远端直肠癌患者中评估在线MR引导反应适应性剂量递增放疗的可行性与结局,采用45 Gy/25次至直肠系膜及髂内淋巴结、50 Gy/25次同步整合推量至原发肿瘤,并每周行3 Gy/次MR-Linac适应推量。4例达临床完全缓解,1例经局部切除证实病理完全缓解,所有PRO-CTCAE 3级毒性在治疗结束后6个月内消退,生活质量和控便功能与基线相当。

要点

  • 在线MR引导反应适应性剂量递增放疗在5例远端直肠癌患者中可行且耐受良好。
  • 4例达临床完全缓解,1例经局部切除证实病理完全缓解。
  • 所有PRO-CTCAE 3级毒性在治疗结束后6个月内消退,生活质量和控便评分与基线相当。

核心结论

  • 在线反应适应性MR引导剂量递增放疗在直肠癌器官保留中似乎非常有前景,可获得高缓解率、良好器官功能和有限副作用。
  • 原文结论指出需要进一步前瞻性评估。

研究设计与样本

  • 共5例直肠癌患者接受45 Gy/25次至直肠系膜及髂内淋巴结、50 Gy/25次同步整合推量至原发肿瘤的常规直线加速器放疗。
  • 每周在1.5 T MR-Linac上安排3 Gy/次的反应适应性推量照射。
  • 治疗第1周和最后1周给予5-氟尿嘧啶持续静脉输注同步化疗。
  • 治疗结束后约3个月评估反应,临床完全缓解或接近临床完全缓解者省略手术。
  • 毒性采用PRO-CTCAE分级,生活质量采用EORTC-QLQ-C30问卷,控便功能采用Wexner量表。

主要发现

  • 反应适应性剂量递增放疗在所有患者中可行且耐受良好。
  • 4例达到临床完全缓解,1例经局部切除证实病理完全缓解。
  • 所有PRO-CTCAE 3级毒性在治疗结束后6个月内消退。
  • 随访期间生活质量和控便评分与基线水平相当。

关键数值与推荐

  • 放疗剂量:45 Gy/25次至直肠系膜及髂内淋巴结,50 Gy/25次同步整合推量至原发肿瘤。
  • 反应适应性推量:3 Gy/次,每周在1.5 T MR-Linac上进行。
  • 同步化疗:5-氟尿嘧啶持续静脉输注,于治疗第1周和最后1周给予。
  • 反应评估时间:治疗结束后约3个月。
  • 省略手术条件:临床完全缓解或接近临床完全缓解。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需要进一步前瞻性评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Non-surgical management of rectal cancer aiming for organ-preservation is an important development to improve rectal cancer treatment. Dose escalated radiotherapy represents one approach to increase clinical complete response (cCR) rates. In the present study we present feasibility and outcome data on rectal cancer patients who were treated with dose escalated radiotherapy using an MR guided online response-adaptive workflow. MATERIAL AND METHODS: A total of five patients were treated with 45 Gy in 25 fractions to the mesorectum and the internal iliac lymph nodes and a simultaneous integrated boost to the primary tumor with 50 Gy in 25 fractions on a conventional linac. In addition, weekly response-adaptive boost fractions with 3 Gy per fraction were scheduled on a 1.5 T MR-Linac. Concomitant chemotherapy with 5-fluorouracil was given as continuous venous infusion during the first and last week of treatment. Response was evaluated approximately-three months after the end of treatment and surgery was omitted in case of a clinical complete response (cCR) or a near cCR. Toxicity was graded by using PRO-CTCAE, Quality of life by the EORTC-QLQ-C30 questionnaire and continence according to the Wexner scale. RESULTS: Response-adaptive dose escalated radiotherapy was feasible and well tolerated by all patients. Four reached a clinical complete response, one had a local excision confirming pathological complete response (pCR). All PRO-CTCAE grade 3 toxicities resolved within six months after the end of treatment. Quality of life and continence scores during follow-up were comparable to baseline levels. CONCLUSION: Dose-escalated online response-adaptive MR-guided radiotherapy appears to be a very promising treatment with the goal of organ preservation in rectal cancer leading to high response rates, excellent organ function and limited side effects. Further prospective evaluation is needed.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Boeke S, Uder L, Ehlers J, et al. Online MR guided dose escalated radiotherapy for organ preservation in distal rectal cancer. Clin Transl Radiat Oncol. 2022. PMID: 36339638. doi:10.1016/j.ctro.2022.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。